Zugrel

Composition: Prasugrel hydrochloride

Form: Film-coated tablets

Indications: Prevention of atherothrombotic complications (myocardial infarction, stroke, cardiovascular death) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI), in combination with acetylsalicylic acid.

Contraindications: Active bleeding, history of stroke or TIA, severe hepatic impairment (class C), hypersensitivity to prasugrel.

Dosage: 60 mg once (loading dose), then 10 mg once daily. For patients <60 kg — 5 mg daily. Always in combination with acetylsalicylic acid (75–325 mg/day).

Side effects: Bleeding, thrombocytopenia, anemia, headache, hypotension, rash, leukopenia, diarrhea, allergic reactions (including anaphylaxis), thrombotic thrombocytopenic purpura.

Interactions: Increased risk of bleeding with NSAIDs, warfarin, anticoagulants, fibrinolytics. Can be used with aspirin, proton pump inhibitors, statins.

Warnings: Use with caution in patients <60 kg, >75 years old, with ulcer disease, surgery, renal/hepatic impairment. Stop at least 7 days before surgery. Platelet transfusion may be required in case of bleeding.

Age restrictions: 18+

Pregnancy: Use only if expected benefit outweighs potential risk. Breastfeeding should be discontinued.

Country of origin: Bangladesh

Manufacturer: Incepta Pharmaceuticals Ltd

Storage conditions: Store below 30°C. Keep out of reach of children.